Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

rtain

investments.

(6) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(7) To exclude the DoD Tricare program reversal as a result of the U.S.

Court of Appeals September 2006 ruling.

(8) To exclude charges associated with the settlement of the PROVIGIL

patent litigation ($6.0 million) and employee severance costs

associated with the European integration and restructuring ($4.0

million).

(9) To exclude charges related to the impairment of an intangible asset.

(10) To exclude the write-off of deferred debt issuance costs related to

the Zero Coupon convertible subordinated notes.

(11) Amounts shown no longer exclude the impact of SFAS 123(R). The

earnings press release issued on November 2, 2006 reflected

adjustments of $11.6 million in each of Research and development and

Selling, general and administrative expenses and $8.8 million in

Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

"ADJUSTED" CONSOLIDATED SALES DETAIL *

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 $217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced ... of,the inaugural companies in the new NASDAQ(R) NeuroInsights(R) ... an index designed to track,the performance of selected ... three major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech ...
... MacroGenics, Inc. announced,today that Mr. Jeffrey H. Buchalter ... of Directors. With more than 20 years of ... and,biotechnology industry, Mr. Buchalter is well poised to ... company matures toward,commercializing its pipeline. "We are ...
... York, September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: ... on September 24, 2007, the Company received a ... comply with the minimum,$10 million shareholders, equity requirement ... set forth in Marketplace Rule 4450(a)(3), and that,its ...
Cached Biology Technology:Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... 22, 2013 U.S. Forest Service scientists are part ... funding from the TKF Foundation, will examine how collaborative ... individuals recover from tragedy. , The TKF Foundation announced ... projects selected for grant funding. In addition to research ... in recovery and resiliency, the 3-year, $585,000 grant will ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... and researchers at John Theurer Cancer Center at HackensackUMC, one ... latest findings in blood-cancer research at the 2012 American Society ... 1-5. Their involvement in these studies is part of John ... "We are proud to make a contribution ...
... According to a new study, children exposed to ... at increased risk for chromosomal aberrations (CAs), which have ... a potentially more harmful and long-lasting subtype of CAs. ... Health (CCCEH) at the Mailman School of Public Health, ...
... Therapeutics Centre (ETC) under the Agency for Science and Technology ... has enabled the successful development of the most comprehensive and ... this highly advanced kit, doctors can now rapidly detect all ... with almost 100% accuracy, within a few hours. This is ...
Cached Biology News:John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
Biology Products: